Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 243

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 243
---
 |
| 75th quantile (95% CI)(2)                                                                |     |    143 (141, 143) |     |         | 126 (87, 146) |
| Comparison to Placebo(3)                                                                 |     | 0.68 (0.54, 0.86) |     |         |               |
| (Hazard ratio [95% CI]):                                                                 |     |           P=0.001 |     |         |               |

| (1) | Censored patients are the following: (1) patients who do not receive a repeat injection of SP-102 and (2) patients who discontinued the study prior to Week 20 without receiving a repeat injection. |

| (2) | Quartiles are estimated using Kaplan-Meier estimation. |

| (3) | A Cox proportional hazards model was utilized to test the treatment difference while adjusting for site and 
 Pain Catastrophizing Scale (<30 or ≥30).                                                                    |

CI: confidence interval; ITT: intent-to-treat(randomized population); SD: standard deviation Responder Analysis (Change from Baseline in Mean NPRS, Average Daily Pain in Affected Leg) (1)– ITT Population

|                                         |     | SP-102            
 N=202             |     | Placebo 
 N=199   |            |
| 30% reduction                           |     | 88 (43.6%)        |     |         | 57 (28.6%) |
| Chi-Square                              |     | P=0.002           |     |         |            |
| Logistic regression(2) (odds ratio [95% 
 CI])                                    |     | 1.96 (1.28, 2.98) |     |         |            |
|                                         |     | P=0.002           |     |         |            |
| 50% reduction                           |     | 58 (28.7%)        |     |         | 41 (20.6%) |
| Chi-Square                              |     | P=0.060           |     |         |            |
| Logistic regression(2) (odds ratio [95% 
 CI])                                    |     | 1.58 (0.99, 2.52) |     |         |            |
|                                         |     | P=0.055           |     |         |            |

| (1) | Patients that discontinued or have missing scores at Week